JP6577683B2 - 安定性に優れるテリパラチド含有液状医薬組成物 - Google Patents

安定性に優れるテリパラチド含有液状医薬組成物 Download PDF

Info

Publication number
JP6577683B2
JP6577683B2 JP2018558440A JP2018558440A JP6577683B2 JP 6577683 B2 JP6577683 B2 JP 6577683B2 JP 2018558440 A JP2018558440 A JP 2018558440A JP 2018558440 A JP2018558440 A JP 2018558440A JP 6577683 B2 JP6577683 B2 JP 6577683B2
Authority
JP
Japan
Prior art keywords
component
liquid pharmaceutical
teriparatide
pharmaceutical preparation
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018558440A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019059302A1 (ja
Inventor
康平 宮部
康平 宮部
山口　貴宏
貴宏 山口
保宏 松縄
保宏 松縄
成実 渡邉
成実 渡邉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Pharma Corp
Original Assignee
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Pharma Corp filed Critical Asahi Kasei Pharma Corp
Application granted granted Critical
Publication of JP6577683B2 publication Critical patent/JP6577683B2/ja
Publication of JPWO2019059302A1 publication Critical patent/JPWO2019059302A1/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2018558440A 2017-09-22 2018-09-20 安定性に優れるテリパラチド含有液状医薬組成物 Active JP6577683B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017182611 2017-09-22
JP2017182611 2017-09-22
PCT/JP2018/034887 WO2019059302A1 (ja) 2017-09-22 2018-09-20 安定性に優れるテリパラチド含有液状医薬組成物

Related Child Applications (4)

Application Number Title Priority Date Filing Date
JP2019008797A Division JP6714738B2 (ja) 2017-09-22 2019-01-22 安定性に優れるテリパラチド含有液状医薬組成物
JP2019008790A Division JP6585317B2 (ja) 2017-09-22 2019-01-22 安定性に優れるテリパラチド含有液状医薬組成物
JP2019041011A Division JP6817358B2 (ja) 2017-09-22 2019-03-06 安定性に優れるテリパラチド含有液状医薬組成物
JP2019040987A Division JP6826140B2 (ja) 2017-09-22 2019-03-06 安定性に優れるテリパラチド含有液状医薬組成物

Publications (2)

Publication Number Publication Date
JP6577683B2 true JP6577683B2 (ja) 2019-09-18
JPWO2019059302A1 JPWO2019059302A1 (ja) 2019-11-14

Family

ID=65811407

Family Applications (17)

Application Number Title Priority Date Filing Date
JP2018558440A Active JP6577683B2 (ja) 2017-09-22 2018-09-20 安定性に優れるテリパラチド含有液状医薬組成物
JP2019008797A Active JP6714738B2 (ja) 2017-09-22 2019-01-22 安定性に優れるテリパラチド含有液状医薬組成物
JP2019008790A Active JP6585317B2 (ja) 2017-09-22 2019-01-22 安定性に優れるテリパラチド含有液状医薬組成物
JP2019041011A Active JP6817358B2 (ja) 2017-09-22 2019-03-06 安定性に優れるテリパラチド含有液状医薬組成物
JP2019040987A Active JP6826140B2 (ja) 2017-09-22 2019-03-06 安定性に優れるテリパラチド含有液状医薬組成物
JP2019057398A Active JP6581741B2 (ja) 2017-09-22 2019-03-25 安定性に優れるテリパラチド含有液状医薬組成物
JP2019057412A Active JP6781790B2 (ja) 2017-09-22 2019-03-25 安定性に優れるテリパラチド含有液状医薬組成物
JP2019057434A Active JP6646173B2 (ja) 2017-09-22 2019-03-25 安定性に優れるテリパラチド含有液状医薬組成物
JP2019057438A Pending JP2019089865A (ja) 2017-09-22 2019-03-25 安定性に優れるテリパラチド含有液状医薬組成物
JP2019057408A Active JP6634175B2 (ja) 2017-09-22 2019-03-25 安定性に優れるテリパラチド含有液状医薬組成物
JP2019085817A Active JP6825034B2 (ja) 2017-09-22 2019-04-26 安定性に優れるテリパラチド含有液状医薬組成物
JP2019228968A Active JP6739612B2 (ja) 2017-09-22 2019-12-19 安定性に優れるテリパラチド含有液状医薬組成物
JP2020053255A Active JP6766286B2 (ja) 2017-09-22 2020-03-24 安定性に優れるテリパラチド含有液状医薬組成物
JP2020139570A Active JP6818928B2 (ja) 2017-09-22 2020-08-20 安定性に優れるテリパラチド含有液状医薬組成物
JP2020201121A Active JP6851536B2 (ja) 2017-09-22 2020-12-03 安定性に優れるテリパラチド含有液状医薬組成物
JP2020218741A Active JP6977137B2 (ja) 2017-09-22 2020-12-28 安定性に優れるテリパラチド含有液状医薬組成物
JP2021036829A Pending JP2021088606A (ja) 2017-09-22 2021-03-09 安定性に優れるテリパラチド含有液状医薬組成物

Family Applications After (16)

Application Number Title Priority Date Filing Date
JP2019008797A Active JP6714738B2 (ja) 2017-09-22 2019-01-22 安定性に優れるテリパラチド含有液状医薬組成物
JP2019008790A Active JP6585317B2 (ja) 2017-09-22 2019-01-22 安定性に優れるテリパラチド含有液状医薬組成物
JP2019041011A Active JP6817358B2 (ja) 2017-09-22 2019-03-06 安定性に優れるテリパラチド含有液状医薬組成物
JP2019040987A Active JP6826140B2 (ja) 2017-09-22 2019-03-06 安定性に優れるテリパラチド含有液状医薬組成物
JP2019057398A Active JP6581741B2 (ja) 2017-09-22 2019-03-25 安定性に優れるテリパラチド含有液状医薬組成物
JP2019057412A Active JP6781790B2 (ja) 2017-09-22 2019-03-25 安定性に優れるテリパラチド含有液状医薬組成物
JP2019057434A Active JP6646173B2 (ja) 2017-09-22 2019-03-25 安定性に優れるテリパラチド含有液状医薬組成物
JP2019057438A Pending JP2019089865A (ja) 2017-09-22 2019-03-25 安定性に優れるテリパラチド含有液状医薬組成物
JP2019057408A Active JP6634175B2 (ja) 2017-09-22 2019-03-25 安定性に優れるテリパラチド含有液状医薬組成物
JP2019085817A Active JP6825034B2 (ja) 2017-09-22 2019-04-26 安定性に優れるテリパラチド含有液状医薬組成物
JP2019228968A Active JP6739612B2 (ja) 2017-09-22 2019-12-19 安定性に優れるテリパラチド含有液状医薬組成物
JP2020053255A Active JP6766286B2 (ja) 2017-09-22 2020-03-24 安定性に優れるテリパラチド含有液状医薬組成物
JP2020139570A Active JP6818928B2 (ja) 2017-09-22 2020-08-20 安定性に優れるテリパラチド含有液状医薬組成物
JP2020201121A Active JP6851536B2 (ja) 2017-09-22 2020-12-03 安定性に優れるテリパラチド含有液状医薬組成物
JP2020218741A Active JP6977137B2 (ja) 2017-09-22 2020-12-28 安定性に優れるテリパラチド含有液状医薬組成物
JP2021036829A Pending JP2021088606A (ja) 2017-09-22 2021-03-09 安定性に優れるテリパラチド含有液状医薬組成物

Country Status (6)

Country Link
US (2) US20200289621A1 (enExample)
EP (1) EP3685849A4 (enExample)
JP (17) JP6577683B2 (enExample)
CN (2) CN116898955A (enExample)
CA (1) CA3075977C (enExample)
WO (1) WO2019059302A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6577683B2 (ja) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
WO2020090174A1 (ja) * 2018-10-29 2020-05-07 旭化成ファーマ株式会社 週２回の頻度でテリパラチド又はその塩を投与することを特徴とする、骨粗鬆症の予防又は治療方法
JP7240407B2 (ja) * 2019-09-05 2023-03-15 旭化成ファーマ株式会社 テリパラチド又はその塩を含有する無菌注射剤を製造する方法
JP6965474B1 (ja) * 2019-12-09 2021-11-10 旭化成ファーマ株式会社 テリパラチド又はその塩を含有するプレフィルドシリンジまたはカートリッジ製剤の振盪による白濁を抑制する方法
AU2020409932B2 (en) * 2019-12-18 2023-09-07 Daewoong Pharmaceutical Co., Ltd. Liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrole-3-yl)-N-methylmethaneamine
WO2021229835A1 (ja) * 2020-05-11 2021-11-18 旭化成ファーマ株式会社 テリパラチド又はその塩を含有する安定な液状医薬製剤
CN114306249A (zh) * 2020-09-28 2022-04-12 深圳翰宇药业股份有限公司 一种特立帕肽冻干药物组合物及其制备方法
CN114031680B (zh) * 2021-09-01 2024-03-26 浙江湃肽生物有限公司 一种索玛鲁肽钠盐及其制备方法与应用
CN114316021A (zh) * 2021-12-29 2022-04-12 江苏诺泰澳赛诺生物制药股份有限公司 一种特立帕肽及的纯化方法
WO2025032376A1 (en) * 2023-08-04 2025-02-13 Precise Biopharma Pvt Ltd A room temperature stable solution for injection of abaloparatide

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6357527A (ja) 1986-08-28 1988-03-12 Toyo Jozo Co Ltd 薬剤の吸着防止方法
JPH0669956B2 (ja) 1988-09-30 1994-09-07 旭化成工業株式会社 ポリペプタイド類の吸着防止剤
NL9001681A (nl) * 1990-07-24 1992-02-17 Rijksuniversiteit Transmucosale geneesmiddelpreparaten en transmucosale toediening.
JP2662842B2 (ja) 1991-12-09 1997-10-15 旭化成工業株式会社 パラサイロイドホルモンの安定化組成物
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
JPH11292787A (ja) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
DE19538687A1 (de) * 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon
MY120063A (en) * 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
JPH11235390A (ja) * 1997-12-12 1999-08-31 Takeda Chem Ind Ltd 経皮透過方法
EA200000672A1 (ru) * 1997-12-18 2000-12-25 Эли Лилли Энд Компани Кристалический терипаратид
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa
DZ2873A1 (fr) * 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
CA2380423A1 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
EP1301200A2 (en) 2000-05-19 2003-04-16 Bionebraska, Inc. Peptide pharmaceutical formulations
ES2267820T3 (es) * 2000-10-09 2007-03-16 Eli Lilly And Company Dispositivo tipo pluma para la administracion de hormona paratiroidea.
DE10116552A1 (de) * 2001-04-03 2002-10-10 Abc Armbruster Biochemicals Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe
EP1391209A4 (en) * 2001-05-30 2009-12-16 Chugai Pharmaceutical Co Ltd PROTEIN PREPARATION
US6896894B2 (en) * 2001-10-30 2005-05-24 Battelle Memorial Institute Proteins stabilized with polysaccharide gums
EP1444263A4 (en) * 2001-11-05 2005-04-20 Lilly Co Eli METHOD FOR IMPROVING THE STABILITY OF A BONE BINDING IMPLANT
JP4252260B2 (ja) * 2002-06-05 2009-04-08 旭化成ファーマ株式会社 Ｐｔｈの安定化水溶液注射剤
JP4607010B2 (ja) * 2003-02-28 2011-01-05 中外製薬株式会社 タンパク質含有安定化製剤
WO2005014034A1 (en) * 2003-07-14 2005-02-17 Nps Allelix Corp. Stabilized formulation of parathyroid hormone
JP4707327B2 (ja) 2004-01-27 2011-06-22 旭化成ファーマ株式会社 ポリペプタイド類の吸着防止剤
CA2567056A1 (en) * 2004-05-10 2005-12-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
CN100566669C (zh) * 2004-05-13 2009-12-09 阿尔扎公司 甲状旁腺激素药物的透皮释放装置
EP1744683B1 (en) * 2004-05-13 2016-03-16 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
CN101022822B (zh) * 2004-08-24 2012-06-27 第一三共株式会社 生理学活性肽的液体制剂
KR100700869B1 (ko) * 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
US20110046059A1 (en) * 2005-09-06 2011-02-24 Zelos Therapeutics, Inc. Pharmaceutically acceptable formulations/compositions for peptidyl drugs
CA2625084A1 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
WO2007044375A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
JP5522879B2 (ja) * 2006-01-16 2014-06-18 旭化成ファーマ株式会社 樹脂容器中の生理活性ペプチドの安定性改善方法
JP2010501476A (ja) * 2006-07-31 2010-01-21 ゼロス セラピューティクス， インコーポレイテッド 副甲状腺ホルモン類似体およびその使用方法
ES2583002T3 (es) * 2007-04-09 2016-09-16 The Board Of Trustees Of The University Of Arkansas Proteínas de fusión de un dominio de enlazamiento a colágeno y hormona paratiroidea
WO2009006097A1 (en) * 2007-06-29 2009-01-08 Johnson & Johnson Regenerative Therapeutics, Llc Liquid protein formulations comprising gdf-5 for use at elevated temperatures
EP2052736A1 (en) * 2007-10-26 2009-04-29 Nycomed Danmark ApS Parathyroid hormone formulations und uses thereof
CN102026619A (zh) * 2008-04-14 2011-04-20 先进科技及再生医学有限责任公司 液体缓冲的gdf-5制剂
WO2010030670A2 (en) * 2008-09-10 2010-03-18 Genentech, Inc. Compositions and methods for the prevention of oxidative degradation of proteins
AU2015201581B2 (en) * 2008-09-17 2017-03-09 Amryt Endo, Inc. Pharmaceutical Compositions and Related Methods of Delivery
EP2358393A1 (en) * 2008-11-20 2011-08-24 F.Hoffmann-La Roche Ag Therapeutic protein formulations
JP2009091363A (ja) * 2008-11-21 2009-04-30 Asahi Kasei Pharma Kk Ｐｔｈの安定化水溶液注射剤
US8481678B2 (en) 2009-03-30 2013-07-09 E I Du Pont De Nemours And Company Peptide-based tooth whitening reagents
WO2011011675A1 (en) 2009-07-23 2011-01-27 Zelos Therapeutics, Inc. Pharmaceutically acceptable formulations/compositions for peptidyl drugs
ES2843649T3 (es) * 2009-09-09 2021-07-20 Asahi Kasei Pharma Corp Agente terapéutico/profiláctico que contiene PTH para la osteoporosis, caracterizado porque la PTH se administra una vez por semana en una dosis unitaria de 200 unidades
WO2011139838A2 (en) 2010-04-28 2011-11-10 Zelos Therapeutics, Inc. Intranasal formulations
WO2012075375A1 (en) * 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of parathyroid hormones by microinjection systems
KR101978527B1 (ko) 2011-03-10 2019-09-03 엑스에리스 파머수티클스, 인크. 펩티드 약물의 비경구 주입을 위한 안정한 제형
ES2761635T3 (es) 2011-06-07 2020-05-20 Asahi Kasei Pharma Corp Preparación liofilizada que contiene PTH de alta pureza y método para producirla
WO2013063280A1 (en) * 2011-10-25 2013-05-02 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
AU2013210689A1 (en) * 2012-01-20 2014-07-31 Lupin Limited Stabilized PTH formulation
SG11201406422TA (en) * 2012-04-09 2014-11-27 Daiichi Sankyo Co Ltd Anti-fgfr2 antibody
CN103301058A (zh) * 2013-06-17 2013-09-18 深圳翰宇药业股份有限公司 一种特立帕肽注射用组合物及其制备方法和制剂
EP3209332B1 (en) * 2014-10-23 2021-05-26 Amgen Inc. Reducing viscosity of pharmaceutical formulations
WO2017007777A2 (en) * 2015-07-06 2017-01-12 Zhengxin Dong NOVEL FORMULATIONS OF PTHrP ANALOGUE
JP6634758B2 (ja) * 2015-09-25 2020-01-22 ニプロ株式会社 液体組成物及び凍結乾燥製剤
JP6641870B2 (ja) * 2015-10-14 2020-02-05 ニプロ株式会社 パラサイロイドホルモン類含有製剤の製造方法
JP2018188399A (ja) * 2017-05-10 2018-11-29 ニプロ株式会社 テリパラチドのプレフィルドシリンジ製剤
JP6577683B2 (ja) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物

Also Published As

Publication number Publication date
JP6826140B2 (ja) 2021-02-03
JP2019073543A (ja) 2019-05-16
US20200289621A1 (en) 2020-09-17
CN116898955A (zh) 2023-10-20
JP2019116513A (ja) 2019-07-18
JP2019116495A (ja) 2019-07-18
CA3075977C (en) 2024-10-29
JP2019081811A (ja) 2019-05-30
EP3685849A4 (en) 2021-12-22
JP2019081812A (ja) 2019-05-30
JP6739612B2 (ja) 2020-08-12
JP2019089865A (ja) 2019-06-13
JP6825034B2 (ja) 2021-02-03
WO2019059302A1 (ja) 2019-03-28
JP2019089862A (ja) 2019-06-13
JP6818928B2 (ja) 2021-01-27
CA3075977A1 (en) 2019-03-28
JPWO2019059302A1 (ja) 2019-11-14
JP2021088606A (ja) 2021-06-10
JP6634175B2 (ja) 2020-01-22
JP6585317B2 (ja) 2019-10-02
JP6646173B2 (ja) 2020-02-14
JP2020186270A (ja) 2020-11-19
JP6714738B2 (ja) 2020-06-24
JP2019089864A (ja) 2019-06-13
JP6977137B2 (ja) 2021-12-08
JP6766286B2 (ja) 2020-10-07
JP6781790B2 (ja) 2020-11-04
JP2021046452A (ja) 2021-03-25
JP6581741B2 (ja) 2019-09-25
JP2020040995A (ja) 2020-03-19
JP6851536B2 (ja) 2021-03-31
US20210205418A1 (en) 2021-07-08
EP3685849A1 (en) 2020-07-29
JP6817358B2 (ja) 2021-01-20
JP2021036000A (ja) 2021-03-04
JP2019089863A (ja) 2019-06-13
JP2020114843A (ja) 2020-07-30
JP2019065042A (ja) 2019-04-25
CN110996988A (zh) 2020-04-10

Similar Documents

Publication Publication Date Title
JP6581741B2 (ja) 安定性に優れるテリパラチド含有液状医薬組成物
US20220096414A1 (en) Levothyroxine liquid formulations
HK40023299A (en) Teriparatide-containing liquid pharmaceutical composition having excellent stability
JP2019156805A (ja) 容器充填ヒトｐｔｈ（１−３４）液体医薬組成物及びその製造方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181207

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20181207

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20181226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190306

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20190411

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190611

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190814

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190822

R150 Certificate of patent or registration of utility model

Ref document number: 6577683

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150